Agios Pharmaceuticals, Inc.
AGIO
$29.20
-$1.03-3.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 86.09% | 43.69% | 44.57% | 6.56% | 51.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.09% | 43.69% | 44.57% | 6.56% | 51.06% |
| Cost of Revenue | 6.98% | 20.80% | 18.69% | 6.62% | 7.68% |
| Gross Profit | 4.60% | -17.61% | -15.52% | -6.62% | -3.34% |
| SG&A Expenses | -0.17% | 7.10% | 29.08% | 33.90% | 46.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.26% | 16.08% | 21.92% | 15.05% | 19.75% |
| Operating Income | 2.77% | -13.67% | -20.07% | -15.81% | -17.65% |
| Income Before Tax | -3.47% | -110.33% | -16.54% | -9.49% | -9.86% |
| Income Tax Expenses | 88.55% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.93% | -110.91% | -16.54% | -9.49% | -0.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.93% | -110.91% | -16.54% | -9.49% | -0.61% |
| EBIT | 2.77% | -13.67% | -20.07% | -15.81% | -17.65% |
| EBITDA | 2.72% | -13.83% | -20.70% | -16.12% | -17.92% |
| EPS Basic | -9.54% | -110.69% | -14.27% | -7.45% | 1.46% |
| Normalized Basic EPS | -1.26% | -14.98% | -14.27% | -7.43% | -7.59% |
| EPS Diluted | -9.54% | -110.97% | -14.27% | -7.45% | 1.67% |
| Normalized Diluted EPS | -1.26% | -18.00% | -14.27% | -7.43% | -7.59% |
| Average Basic Shares Outstanding | 2.19% | 2.11% | 1.99% | 1.91% | 2.10% |
| Average Diluted Shares Outstanding | 2.19% | -0.50% | 1.99% | 1.91% | 2.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |